Zachary Epstein-Peterson, MD

home / authors / zachary-epstein-peterson-md

Articles

Zachary Epstein-Peterson, MD

Dr Epstein-Peterson on the Use of CAR T-Cell Therapy in MCL

Zachary Epstein-Peterson, MD
April 7th 2023

Zachary Epstein-Peterson, MD, discusses the use of CAR T-cell therapy in mantle cell lymphoma and highlights questions that remain to be answered within the treatment landscape.

Read More

Zachary Epstein-Peterson, MD

Dr Epstein-Peterson on the Treatment of Transplant-Eligible and -Ineligible Patients with MCL

Zachary Epstein-Peterson, MD
April 6th 2023

Zachary Epstein-Peterson, MD, discusses available treatment approaches for patients with mantle cell lymphoma who are transplant eligible or ineligible.

Read More

Zachary Epstein-Peterson, MD

Dr. Epstein-Peterson on Disease Observation and TP53 Mutations in MCL

Zachary Epstein-Peterson, MD
March 16th 2023

Zachary Epstein-Peterson, MD, discusses important updates in mantle cell lymphoma treatment, including the safety and feasibility of disease observation in patients with indolent MCL and the treatment of patients with TP53-mutated MCL.

Read More

Zachary Epstein-Peterson, MD

Dr. Epstein-Peterson on Pivotal Clinical Trials in MCL

Zachary Epstein-Peterson, MD
November 14th 2022

Zachary Epstein-Peterson, MD, discusses pivotal clinical trials in the treatment of patients with mantle cell lymphoma.

Read More

Zachary Epstein-Peterson, MD

Dr. Epstein-Peterson on the Importance of Treatment Sequencing Decisions in MCL

Zachary Epstein-Peterson, MD
November 4th 2022

Zachary Epstein-Peterson, MD, discusses the importance of treatment sequencing decisions in mantle cell lymphoma.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need